Press Releases Actinium Pharmaceuticals, Inc.

Equities

ATNM

US00507W2061

Market Closed - Nyse Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
8.15 ^USD	+0.49%		-3.21%	+60.43%

May. 20	Transcript : Actinium Pharmaceuticals, Inc. - Special Call
May. 15	Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in Tp53 Positive Patients At the Eha 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 Sierra Trial	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Actinium Pharmaceuticals (ATNM) Poised for Breakout as Analysts Project Significant Upside	May. 09	AQ
Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML	Apr. 19	AQ
Actinium Pharmaceuticals (ATNM) Garners Attention with Clinical Successes and Strategic Market Moves Amid Growing Radiopharma Interest	Apr. 17	AQ
Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation	Apr. 02	AQ
InvestorBrandMedia: Wall Street Bulls Eye a 290% Upside on Actinium Pharmaceuticals, Inc. (NYSEAMERICAN: ATNM) Amidst Groundbreaking Cancer Therapy Innovations	Apr. 01	AQ
Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey	Mar. 28	AQ
Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy	Mar. 27	AQ
InvestorBrandMedia: FDA Approves Vertex Pharmaceuticals (NASDAQ:VRTX) VX-407 for Phase I Study in Groundbreaking Move Against Polycystic Kidney Disease"	Mar. 25	AQ
InvestorBrandMedia: Actinium Pharmaceuticals Inc (ATNM) Targets Breakthrough in Cancer Therapy: Proprietary Production of Vital Isotope Sparks Industry Buzz and Share Surge	Mar. 21	AQ
InvestorBrandMedia: Actinium Pharmaceuticals Inc. (ATNM) Leads Breakthroughs in Targeted Radiotherapy with Iomab-B and Strategic Production of Actinium-225	Mar. 20	AQ
Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial	Feb. 27	AQ
Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings	Feb. 26	AQ
Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings, Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR	Jan. 03	AQ
Actinium s Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia	Dec. 12	AQ
Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation	Dec. 12	AQ
Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting and Exposition	Dec. 11	AQ
ASH 2023: High Dose Targeted Radiotherapy via Iomab-B Prior to BMT Produces Durable Complete Remissions	Dec. 07	PU
ASH 2023: Iomab-B Produces Long Term Remissions Irrespective of Multiple High-Risk Features	Dec. 07	PU
ASH 2023 Oral Presentation: Iomab-B Improves Survival in Patients with R/R AML and TP53 Mutation	Dec. 07	PU
Actinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy Combinations	Nov. 07	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Actinium Pharmaceuticals, Inc.

Equities

ATNM

US00507W2061

Press Releases

Filters